Matthew P Gray
Overview
Explore the profile of Matthew P Gray including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
277
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gray M, Kellum J, Kirisci L, Boyce R, Kane-Gill S
JAMA Netw Open
. 2024 May;
7(5):e2412313.
PMID: 38758551
Importance: β-lactam (BL) allergies are the most common drug allergy worldwide, but most are reported in error. BL allergies are also well-established risk factors for adverse drug events and antibiotic-resistant...
2.
Chinta S, Gray M, Kopetsky M, Baumer-Mouradian S, Drendel A, Roth E, et al.
Pediatr Qual Saf
. 2024 Apr;
7(4):e576.
PMID: 38585423
Introduction: Testicular torsion (TT) is a urologic emergency that requires timely diagnosis and surgery. We noted variation in the door-to-detorsion times for patients with TT at our institution and our...
3.
McLaughlin K, Jabbar F, Kelly L, Jovanovic I, Gray M, Charalambous C, et al.
J Hand Surg Eur Vol
. 2023 Nov;
49(5):564-569.
PMID: 37987674
Level Of Evidence: IV.
4.
Stottlemyer B, McDermott M, Minogue M, Gray M, Boyce R, Kane-Gill S
Ther Adv Drug Saf
. 2023 Jun;
14:20420986231181334.
PMID: 37332887
Objective: Between 2012 and 2017, the U.S. Food and Drug Administration (FDA) approved 10 antidiabetic indicated therapies. Due to the limited literature on voluntarily reported safety outcomes for recently approved...
5.
Gray M, Barreto E, Schreier D, Kellum J, Suh K, Kashani K, et al.
Drug Saf
. 2022 Apr;
45(4):389-398.
PMID: 35389144
Introduction: The approach to evaluating nephrotoxins in studies of drug-associated acute kidney injury varies. Some studies use a list of under ten drugs for evaluation whereas others include over 100...
6.
Kim H, Pfeiffer C, Gray M, Stottlemyer B, Boyce R, Kane-Gill S
Respir Care
. 2021 Jun;
66(11):1739-1745.
PMID: 34103383
Background: Between 2012 and 2017, 25 new medications or combination products were approved by the Food and Drug Administration (FDA) for use in treatment of chronic lower respiratory diseases (CLRDs)....
7.
Patel N, Stottlemyer B, Gray M, Boyce R, Kane-Gill S
Cardiovasc Drugs Ther
. 2021 Feb;
36(2):309-322.
PMID: 33599896
Purpose: Between 2012 and 2017, the FDA approved 29 therapies for a cardiovascular disease (CVD) indication. Due to the limited literature on patient safety outcomes for recently approved CVD medications,...
8.
Moreland-Head L, Coons J, Seybert A, Gray M, Kane-Gill S
J Cardiovasc Pharmacol Ther
. 2021 Jan;
26(4):341-348.
PMID: 33403858
Introduction: Drug-induced QT-prolongation is a well-known adverse drug reaction (ADR), however there is limited knowledge of other drug-induced arrhythmias. Purpose: The objective of this study is to determine the drugs...
9.
Andreaggi C, Novak E, Mirabile M, Sampathkumar S, Gray M, He M, et al.
Pharmacoepidemiol Drug Saf
. 2020 Aug;
29(12):1627-1635.
PMID: 32851782
To perform an in-depth analysis of opioid-related ADRs reported by consumers, manufacturers and healthcare professionals. Delving into the depth and breadth of reported opioid-related adverse drug reactions (ADRs) provides an...
10.
Baumer-Mouradian S, Kleinschmidt A, Servi A, Jaworski B, Lazarevic K, Kopetsky M, et al.
Pediatr Qual Saf
. 2020 Aug;
5(4):e322.
PMID: 32766495
Introduction: Annual influenza vaccination is recommended for all US children 6 months and older to prevent morbidity and mortality. Despite these recommendations, only ~50% of US children are vaccinated annually....